Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pyridoxal phosphate - Medicure

Next Previous
Drug Profile

Pyridoxal phosphate - Medicure

Alternative Names: Avastrem; Cardoxal; MC-1; Pyridoxal 5'-phosphate; Tardoxal

Latest Information Update: 25 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Medicure
  • Class Anti-ischaemics; Antiepileptic drugs; Coenzymes; Ischaemic heart disorder therapies; Picolines; Small molecules; Vascular disorder therapies
  • Mechanism of Action Purinergic P2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Seizures
  • New Molecular Entity Yes
  • Available For Licensing Yes - Drug-induced dyskinesia

Highest Development Phases

  • Phase III Seizures
  • Phase II Drug-induced dyskinesia
  • Discontinued Lipid metabolism disorders; Myocardial infarction; Reperfusion injury; Stroke

Most Recent Events

  • 23 Apr 2024 Pyridoxal phosphate receives Fast Track designation for Seizures (associated with Pyridoxamine 5'-phosphate oxidase deficiency) in USA
  • 16 Feb 2024 Phase-III clinical trials in Seizures in USA (PO) (NCT04706013)
  • 19 May 2023 Pyridoxal phosphate is still in preclinical development for Seizure associated with Pyridoxamine 5'-phosphate oxidase deficiency in Canada

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top